Longer-term immunologic effects and side effects of successful antiretroviral therapy

Clinical Infectious Diseases

Volumn 29, Issue 1, 1999, Pages 12-18

  Schooley, Robert T ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELL ACTIVATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPERLIPIDEMIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0032771991     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520139     Document Type: Conference Paper

References (49)

1. 1. Morse GD, Shelton MJ, O'Donnell AM. Human immunodeficiency virus (HIV) infection. In: Young LY, Koda-Kimble MA, eds. Applied therapeutics: the clinical use of drugs. 6th ed. Vancouver, WA: Applied Therapeutics, 1995:68-1 68-48.
2. 2. Fauci AS, Lane HC. Human immunodeficiency virus (HIV) disease: AIDS and related disorders. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, 1994:1566-617.
3. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997;3:533-40.
4. 4. Panel on Clinical Practices for Treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: US Department of Health and Human Services, 1997.
5. 5. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-92.
6. 6. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society - USA Panel. JAMA 1997;277:1962-9.
7. 7. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
8. 8. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
9. 9. Tsoukas CM, Bernard NF. Markers predicting progression of human immunodeficiency virus related disease. Clin Microbiol Rev 1994;7:14-28.
10. 10. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis of HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
11. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
12. - lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
13. + cell count. JAMA 1998;279:35-40.
14. 14. Moore RD. Human immunodeficiency virus infection, anemia, and survival. Clin Infect Dis 1999;29:44-9.
15. 15. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-14.
16. 16. Notermans DW, Jurriaans S, de Wolf F, et al. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine, and zidovudine. AIDS 1998;12:167-73.
17. 17. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, vidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
18. 18. Gulick M, Mellors JW, Havlir D, et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. JAMA 1998;280:34-41.
19. 19. Saag M, Gersten M, Chang Y, et al. Long term virological and immunological effect of the HIV-protease inhibitor, Viracept (nelfinavir mesylate, NFV), in combination with zidovudine (AZT) and lamivudine (3TC) [abstract no. 313]. In: Program and abstracts of the 35th annual meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 1997:112.
20. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
21. 21. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
22. 22. Li TS, Tubiana R, Calvez V, et al. Long term immune recovery in CD4 and CD8 T cells with highly active anti-retroviral therapy [abstract no. 172]. In: Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 1998.
23. 23. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
24. 24. Ravaux I, Chadapavd S, Quinson AN, et al. Discontinue primary prophylaxis regimens in selected HIV-infected patients treated with HAART [abstract no. 31225]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998.
25. 25. Vazquez EG, Marrero Frances J, Garcia Delgado R, et al. Withdrawal of Pneumocystis carinii pneumonia (PCP) prophylaxis after HAART in patients with AIDS [abstract no. 22186]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998.
26. 26. Tortajada C, Martinez E, Miro JM, et al. Withdrawal of primary prophylaxis against P. carinii and T. gondii in adult HIV-1 infected individuals with stable CD4 cell count above 200/μL [abstract no. 22179]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998.
27. 3) due to aggressive antiretroviral therapy [abstract no. LB-11]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.
28. 28. Macdonald JC, Torriani FJ, Morse LS, Karavellas M, Reed JB, Freeman WR. Lack of progression and reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998;177:1182-7.
29. 29. Jouan M, Saves M, Tubiana R, et al. RESTIMOP (ANRS 078): a prospective multicenter study to evaluate the discontinuance of maintenance therapy for CMV retinitis in HIV-patients receiving HAART [abstract no. 456]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 1999.
30. 30. Tural C, Sierra G, Romeu J, et al. A 24 month follow-up of cytomegalovirus retinitis without secondary prophylaxis following highly active antiretroviral therapy [abstract no. 455]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 1999.
31. 31. Lopez JC, Pena JM, Miro JM, Podzamczer D, GESIDA 04/98 Study Group. Discontinuation of PCP prophylaxis is safe in HIV-infected patients with immunological recovery with HAART. Preliminary results of an open, randomized, and multicentric trial [abstract no. LB7]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 1999.
32. 32. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998;351:723-4.
33. 33. Wong JK, Hezareh M, Gunthad HF, et al. Recovery of replication competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
34. 34. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300.
35. 35. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-7.
36. + T cell responses associated with control of viremia. Science 1997;278:1447-50.
37. 37. Rinaldo C, Huang XL, Fran J, et al. Prolonged suppression of HIV-1 viremia results in profound but incomplete enhancement of anti-HIV-1 CTI.m responses in advanced infection [abstract no. 31124]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998.
38. 38. Giorgi JV. Phenotype and function of T cells in HIV disease. In: Gupta S, ed. Immunology of HIV immune function. New York: Plenum, 1996:181-99.
39. + repertoire during antiviral therapy. Nat Med 1998;4:215-21.
40. 40. Gorochov G, Neumann AU, Kereveur A, et al. Disordering of CD4 and CD8 T-cell repertoires during progression to AIDS and restoration of the CD4 repertoire under antiviral therapy [abstract no. 154]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 1998.
41. 41. Rocderer M. Getting to the HAART of T cell dynamics. Nat Med 1998;4:145-46.
42. 42. Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther 1998;20:2-25.
43. 43. Roberts AD, Muesing RA, Parenti DM, Hsia J, Wasserman AG, Simon GL. Alterations in serum lipids and lipoproteins with indinavir in HIV-infected patients [abstract no. 205]. In: Program and abstracts of the 35th annual meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 1997.
44. 44. Keruly JC, Chaisson RE, Moore RD. Diabetes and hyperglycemia in patients receiving protease inhibitors [abstract no. 415]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 1998.
45. 45. Carr A, Samaras K, Burton S, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance due to HIV protease inhibitors (PIs) [abstract no. 410]. In: Program and abstracts of the 5th Conference on Retrovirology and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 1998.
46. 46. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-3.
47. 47. Mann M, Piazza-Hepp T, Koller E, Gibert C. Abnormal fat distribution in AIDS patients following protease inhibitor therapy: FDA summary [abstract no. 412]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 1998.
48. 48. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351:867-70.
49. 49. Dong BJ, Gruta C, Legg J, Balano K, Goldschmit RH. Diabetes and the use of protease inhibitors [abstract no. 416]. In: Program and abstracts of the 5th Conference on Retrovirology and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 1998.